DOCSLIB.ORG

00-Pages 1 . 10

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
00-Pages 1 . 10 Le POPI est un livre distribué gracieusement en France par les ensei- gnants de Pathologie Infectieuse et Tropicale aux étudiants de DCEM 2 ou 3 (Module VII) et DCEM 4. Certains annonceurs distribuent également le POPI aux médecins des hôpitaux. Pour obtenir le POPI en dehors de cette diffusion, il faut en faire la demande auprès de 2M2 (à partir de novembre 2003). Adresse internet : [email protected] Adresse : 2M2 (demande de POPI) - 7, rue Bastienne - 95160 Montmorency. Licence d’utilisation et précautions d’usage Le CMIT (Collège des Enseignants de Médecine Infectieuse et Tropicale) décline toute res- ponsabilité, de quelque nature qu’elle soit, pouvant résulter d’une négligence ou d’une mauvai- se utilisation de tous produits, instruments, techniques ou concepts présentés dans ce livre. Le CMIT recommande qu’une vérification extérieure intervienne pour les diagnostics, posolo- gies et techniques. ISBN CMIT : 2-913057-02-0 © Copyright La loi du 11 mars 1957 interdit les copies ou reproductions destinées à une utilisation collecti- ve. Toute représentation ou reproduction intégrale ou partielle faite par quelque procédé que ce soit, sans le consentement de l'auteur ou ses ayants cause, est illicite et constitue une contrefa- çon sanctionnée par les articles 425 et suivants du Code Pénal. Préface L’édition du POPI 2003 est la 8e. Comme les éditions précédentes, depuis janvier 1990, il s’agit d’un ouvrage collectif, rédigé par les membres du Collège des Universitaires de Maladies infectieuses et Tropicales,le CMIT, ex-APPIT Régulièrement revu, le POPI tient compte de l’évolution rapide de l’infectiologie, en par- ticulier des innovations diagnostiques et thérapeutiques, des récentes conférences d’experts et de consensus, des dernières recommandations de bonne pratique, des documents réglementaires du Ministère de la Santé. Le POPI rassemble sous un faible volume, facile à glisser dans une poche et à consulter, les bases minimums du traitement des infections et ce que l’on ferait si l’on avait une expérien- ce régulière de la situation à laquelle on doit faire face. La création des médecins référents en antibiothérapie et autres traitements anti-infectieux dans les établissements de santé, par la circulaire du 2 mai 2002 (circulaire DHOS/E2- DGS/SD5A- N° 272), est une mesure heureuse pour améliorer la prise en charge des malades ayant une infection et lutter contre la résistance bactérienne aux antibiotiques. Le POPI, tout naturellement, par l’expertise nationale que représente ses auteurs, est l’ouvrage de référence de tous les médecins hospitaliers en contact permanent avec les malades. Sa mise en ligne sur internet (infectiologie.com) et l’intranet des établissements de santé et universitaires sera une nouvelle étape pour faciliter son accès et son utilisation. Que le Comité de rédaction soit remercié de mettre de nouveau à notre disposition un outil bien vivant car actualisé et riche de synthèses fruits d’une longue expérience clinique et rédac- tionnelle. Professeur Patrick CHOUTET, Président du CMIT Auteurs du POPI C. Bazin J. Delmont Th. May A. Stein G. Beaucaire M. Dupon M.C. Meyohas M. Strobel B. Becq- B. Dupont C. Michelet R. Verdon Giraudon J. Frottier M. Micoud J.L. Vildé L. Bernard H. Gallais J. Modaï D. Vittecoq J.M. Besnier M. Garré J.M. Molina P. Weinbreck J. Beytout P.M. Girard Y. Mouton P. Yeni O. Bouchaud B. Guéry C. Perronne Co-auteurs A. Bourgeade B. Hoen D. Peyramond P. Berthelot E. Bouvet G. Humbert G. Pialoux J.P. Brion F. Bricaire F. Janbon E. Pichard Comité de P. Brouqui C. Katlama L. Piroth rédaction Ph. Canton J.Y. Lacut H. Portier G. Beaucaire F. Caron Ch. Lafaix C. Rabaud J.M. Besnier E. Caumes H. Laurichesse F. Raffi P. Chavanet P. Chavanet M. Le Bras J.M. Ragnaud H. Portier C. Chidiac C. Lecacheux G. Rémy F. Raffi P. Choutet C. Leport J. Reynes D. Salmon-Ceron D. Christmann O. Lortholary M. Robineau Coordination J.P. Coulaud F. Lucht R. Roué† M. Garré T. Debord D. Malvy W. Rozenbaum D. Peyramond J.M. Decazes B. Marchou D. Salmon-Céron E. Delaporte P. Massip J.L. Schmit P. Dellamonica S. Matheron J.P. Stahl Sommaire Partie I : infections par site Partie III : infections 1. Définitions 11 et situations à risques 2. Bactériémies 13 29. Infections nosocomiales 185 3. Choc septique 17 30. Bioterrorisme 204 4. Endocardites infectieuses 22 31. Accidents d'exposition aux liquides 209 5. Conduite thérapeutique pratique 31 biologiques devant une méningite aiguë 32. Antibioprophylaxie en chirurgie 214 6. Infections du système nerveux 43 33. Infections chez le toxicomane 225 central (méningites exceptées) 34. Infections chez le granulopénique 227 7. Infections bronchopulmonaires 46 35. Infections et greffes 230 communautaires 36. Infections et immunodépression 232 8. Péricardites infectieuses 56 (en dehors de l’infection par le VIH) 9. Diarrhées infectieuses aiguës 59 37. Fièvre et grossesse 235 10. Infections abdominales 62 38. Fièvre au retour d’Outre-mer 242 11. Infections génitales et MST 66 Partie IV : anti-infectieux 12. Infections urinaires 72 39. Antibiotiques : règles d'utilisation 252 13. Infections cutanées 80 40. Anti-infectieux et interférences 259 14. Infections des parties molles 86 médicamenteuses 15. Adénopathies infectieuses 89 41. Antibiotiques et antiviraux 269 16. Infections par inoculation 93 42. Antifongiques et traitement 278 17. Infections ostéo-articulaires 98 des mycoses 18. Infections ORL 105 43. Antiparasitaires 285 19. Infections bucco-dentaires 114 44. Anti-inflammatoires en pathologie 292 20. Infections oculaires 121 infectieuse Partie II : infections par germe 45. Antiseptiques 294 46. Hygiène et isolement 297 21. Infections à BGN 125 47. Vaccinations 306 22. Infections sévères à staphylocoque 131 48. Maladies à déclaration obligatoire, 315 23. Infections sévères à streptocoque 134 éviction, prophylaxie collective et entérocoque 24. Tuberculose 138 Partie V : annexes 25. Hépatites virales 143 A1. Centres nationaux de référence 317 26. Infections à Herpès virus 154 A2. Centres de vaccination anti-amarile 320 27. Infection par VIH, SIDA 162 A3. Centres de traitement antirabiques 323 28. Maladies à prions : 180 A4. CDAG 324 préventions en milieu hospitalier A5. CISIH 324 A6. Index 326 A7. Abréviations 334 Membres de l’Association des Enseignants de Maladies Infectieuses et Tropicales Pr C. Bazin Pr J.M. Besnier Pr E. Bouvet CHU de la Côte de Nacre Hôpital Bretonneau Hôp Bichat Claude Sce des mal. inf. et trop. Sce des mal. inf. et trop. Bernard Av. de la Côte de Nacre 2 bis, bd Tonnellé Sce des mal. inf. et trop. 14033 Caen Cedex 37044 Tours Cedex 46, Rue Henri Huchard Tél : 02 31 06 47 14 Tél : 02 47 47 37 14 75018 Paris Fax : 02 31 06 49 96 Fax : 02 47 47 37 31 Tél : 01 40 25 73 76 [email protected] [email protected] Fax : 01 40 25 88 40 elisabeth.bouvet@ Pr G. Beaucaire Pr J. Beytout bch.ap-hop-paris.fr Unité d’Infectiologie. Hôpital de l'Hôtel Dieu Pavillon Christiaens Sce des mal. inf. et trop. Pr F. Bricaire Hôpital Albert Calmette. 63000 Clermont-Ferrand Hôpital Pitié Salpétrière CHRU de Lille Tél : 04 73 75 00 65 Sce des mal. inf. et trop. 59037 Lille Cedex Fax : 04 73 75 00 67 47, Boulevard de l'Hôpital Tél : 03 20 44 52 54 jbeytout@ 75013 Paris cedex 13 Fax : 03 20 44 49 42 chu-clermontferrand.fr Tél : 01 42 16 01 01 [email protected] Fax : 01 42 16 01 65 Pr O. Bouchaud francois.bricaire@ Pr B. Becq-Giraudon Hôpital Avicenne psl.ap-hop-paris.fr CHU Jean Bernard Sce des mal. inf. et trop. Sce des mal. inf. et trop. 125, route de Stalingrad Pr P. Brouqui BP 577 93009 Bobigny cedex Hôpital Nord 86021 Poitiers Cedex Tél : 01 48 95 54 21 Sce des mal. inf. et trop. Tél : 05 49 44 44 22 Fax : 01 48 95 54 28 Chemin des Bourrelly Fax : 05 49 44 43 83 olivier.bouchaud@ 13915 Marseille Cedex 20 b.becq-giraudon@ avc.ap-hop-paris.fr Tél : 04 91 96 89 35 chu-poitiers.fr Fax : 04 91 96 89 38 Pr A. Bourgeade [email protected] Pr L. Bernard 29, Rue Cardinale Hôpital Raymond Poincaré 13100 Aix en provence Pr Ph. Canton Sce des mal. inf. et trop. Tél : 04 42 38 45 08 CHU de Brabois 104, bd Raymond Poincaré Fax : 04 42 38 45 08 Sce des mal. inf. et trop. 92380 Garches auguste.bourgeade@ Tour PL Drouet Tél : 01 47 10 77 58 wanadoo.fr 54500 Vandoeuvre Les Fax : 01 47 10 77 67 Nancy [email protected] Tél : 03 83 15 41 24 paris.fr Fax : 03 83 15 35 34 [email protected] 6 Membres du CMIT Pr F. Caron Pr D. Christmann Pr P. Dellamonica Hôpital Charles Nicolle Hôpitaux Universitaires Hôpital de l'Archet 1 Sce des mal. inf. et trop. Sce des mal. inf. et trop. Sce des mal. inf. et trop. 1, Rue de Germont BP 426 BP 3079 76031 Rouen cedex 67091 Strasbourg cedex 06202 Nice cedex 3 Tél : 02 32 88 87 39 Tél : 03 88 11 65 86 Tél : 04 92 03 55 15 Fax : 02 32 88 82 75 Fax : 03 88 11 64 64 Fax : 04 93 96 54 54 Francois.Caron@ Daniel.Christmann@ mal-infectieuses@ chu-rouen.fr chru-strasbourg.fr chu-nice.fr (secrétaire) Pr E. Caumes Pr J.P. Coulaud Pr J. Delmont Hôpital Pitié-Salpétrière Hôp Bichat-Claude Hôpital Nord Sce des mal. inf. et trop. Bernard Sce des mal. inf. et trop. 47, Bld de l'Hôpital Sce des mal. inf. et trop. Chemin des Bourrely 75013 Paris cedex 13 46, Rue Henri Huchard 13915 Marseille cedex 20 Tél : 01 42 16 01 14 75018 Paris Tél : 04 91 96 89 35 Fax : 01 42 16 01 65 Tél : 01 44 85 63 01 Fax : 04 91 96 89 38 eric.caumes@ Fax : 01 44 85 63 04 [email protected] psl.ap-hop-paris.fr [email protected] Pr M.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • UTILISATION DES ANTI-INFECTIEUX ET GROSSESSE Ce Tableau N’A Qu’Une Valeur Indicative Et Ne Constitue Qu’Une Aide À La Prescription
    UTILISATION DES ANTI-INFECTIEUX ET GROSSESSE Ce tableau n’a qu’une valeur indicative et ne constitue qu’une aide à la prescription. L’évaluation devra se faire au cas par cas. Pour plus d’information, contacter le Centre Régional de Pharmacovigilance au 04 73 75 48 31. CONDUITE A TENIR D’UTILISATION ANTI-INFECTIEUX 1er TRIMESTRE 2ème TRIMESTRE et 3ème TRIMESTRE · Possible : 1ère intention : amoxicilline, ampicilline, Pénicilline V, G, amoxicilline-acide clavulanique PENICILLINES · Possible : 2ème intention : cloxacilline, oxacilline, ampicilline-sulbactam, pipéracilline, pipéracilline-tazobactam, ticarcilline, ticarcilline-acide clavulanique · Possible : 1ère intention : C1G (céfadroxil, céfalexine, cefaclor) ; C2G (céfuroxime) ; C3G (ceftriaxone) · Possible : 2ème intention : C1G (céfalotine, céfatrizine, céfazoline, céfradine), C2G (céfamandole, cefoxitine) ; C3G (céfotaxime, ceftazidime, céfépime, CEPHALOSPORINES cefpirome, cefixime, cefotiam, cefpodoxime) · A éviter par prudence : ceftaroline AUTRES BETALACTA- · Possible : 2ème intention : imipénem –cilastatine MINES · A éviter par prudence : aztréonam, doripénème, ertapénème, méropénem · Possible 1ère intention : azithromycine, érythromycine, spiramycine · Possible 2ème intention : josamycine, clarithromycine, roxithromycine MACROLIDES · A éviter par prudence : midécamycine · Déconseillé : télithromycine STREPTOGRAMINES · Possible 2ème intention : pristinamycine · Possible 1ère intention : clindamycine · Possible 1ère intention : clindamycine LINCOSAMIDES · A éviter : lincomycine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T (51) International Patent Classification: AN, Martine; Epichem Pty Ltd, Murdoch University Cam Λ 61Κ 31/155 (2006.01) C07D 249/14 (2006.01) pus, 70 South Street, Murdoch, Western Australia 6150 A61K 31/4045 (2006.01) C07D 407/12 (2006.01) (AU). ABRAHAM, Rebecca; School of Animal and A61K 31/4192 (2006.01) C07D 403/12 (2006.01) Veterinary Science, The University of Adelaide, Adelaide, A61K 31/341 (2006.01) C07D 409/12 (2006.01) South Australia 5005 (AU). A61K 31/381 (2006.01) C07D 401/12 (2006.01) (74) Agent: WRAYS; Groud Floor, 56 Ord Street, West Perth, A61K 31/498 (2006.01) C07D 241/20 (2006.01) Western Australia 6005 (AU). A61K 31/44 (2006.01) C07C 211/27 (2006.01) A61K 31/137 (2006.01) C07C 275/68 (2006.01) (81) Designated States (unless otherwise indicated, for every C07C 279/02 (2006.01) C07C 251/24 (2006.01) kind of national protection available): AE, AG, AL, AM, C07C 241/04 (2006.01) A61P 33/02 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07C 281/08 (2006.01) A61P 33/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07C 337/08 (2006.01) A61P 33/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07C 281/18 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/AU20 15/000527 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 28 August 2015 (28.08.2015) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,504,381 B2 Mor Et Al
    USOO7504381 B2 (12) United States Patent (10) Patent No.: US 7,504,381 B2 Mor et al. (45) Date of Patent: Mar. 17, 2009 (54) ANTIMICROBIAL AGENTS Tossi et al. "Amphipathic, Alpha-Helical Antimicrobial Peptides'. Biopolymers, 55(1): 4-30, 2000. Abstract, Table 1, p. 7-8, Table II, p. (75) Inventors: Amram Mor, Haifa (IL); Inna 13. Radzishevsky, Haifa (IL) Huang "Peptide-Lipid Interactions and Mechanisms of Antimicro bial Peptides”, Novartis Found Symposium, 225: 188-200, 1999. (73) Assignee: Technion Research & Development Discussion 200-206. Epand et al. “Mechanisms for the Modulation of Membrane Bilayer Foundation Ltd., Haifa (IL) Properties by Amphipathic Helical Peptides'. Biopolymers, 37(5): 319-338, 1995. Abstract. (*) Notice: Subject to any disclaimer, the term of this Ono et al. “Design and Synthesis of Basic Peptides Having patent is extended or adjusted under 35 Amphipathic Beta-Structure and Their Interaction With U.S.C. 154(b) by 153 days. Phospholipid Membranes'. Biochimica et Biophysica Acta (BBA) Biomembranes, 1022(2): 237-244, 1990. Abstract. (21) Appl. No.: 11/234,183 Aarbiou et al. “Human Neutrophil Defensins Induce Lung Epithelial Cell Proliferation. In Vitro”, Journal of Leukocyte Biology, 72: 167 (22) Filed: Sep. 26, 2005 174, 2002. Acar “Consequences of Bacterial Resistance to Antibiotics in Medi (65) Prior Publication Data cal Practice'. Clinical Infectious Diseases, 24(Suppl. 1): S17-S18. 1997. US 2006/OO74O21 A1 Apr. 6, 2006 Alan et al. “Expression of A Magainin-Type Antimicrobial Peptide Gene (MSI-99) in Tomato Enhances Resistance to Bacterial Speck Related U.S. Application Data Disease'. Plant Cell Reports, 22:388-396, 2004.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]